All In Biotech

Drug Trial Radar · NCT04412863

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination With Pegylated Interferon Alpha-2a

Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

84

Actual

Start

Jul 3, 2020

Primary completion

Mar 25, 2024

Study completion Mar 25, 2024

Sponsor

Lead sponsor
Vir Biotechnology, Inc.Industry
Sponsor type
Industry
Collaborators
Alnylam Pharmaceuticals
First posted
Jun 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.

Conditions

  • Chronic Hepatitis B

Interventions

  • VIR-2218Drug

    VIR-2218 given by subcutaneous injection

  • pegylated interferon-alfa 2aDrug

    pegylated interferon-alfa 2a given by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Adverse Events as Assessed by CTCAE v5.0Time frame: Up to 148 Weeks
  2. Number of Subjects With Abnormalities in Vital Signs, Electrocardiogram (ECG), and Clinically Significant Laboratory FindingsTime frame: Up to 148 Weeks

Locations

22 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigative Site

    Birtinya, Queensland, Australia

  • Investigative Site

    Fitzroy, Victoria, Australia

  • Investigative site

    Hong Kong, Hong Kong

  • Investigative Site

    Batu Caves, Malaysia

  • Investigative Site

    Kajang, Malaysia

  • Investigative Site

    Kuala Lumpur, Malaysia

  • Investigative Site

    Kuantan, Malaysia

  • Investigative Site

    Auckland, New Zealand

  • Investigative Site

    Auckland, New Zealand

  • Investigative Site

    Busan, South Korea

  • Investigative Site

    Chuncheon, South Korea

  • Investigative Site

    Daegu, South Korea

  • Investigative Site

    Seoul, South Korea

  • Investigative Site

    Seoul, South Korea

  • Investigative Site

    Yangsan, South Korea

  • Investigative Site

    Bangkok, Thailand

  • Investigative Site

    Bangkok, Thailand

  • Investigative Site

    Bangkok, Thailand

  • Investigative Site

    Chiang Mai, Thailand

  • Investigative Site

    Hat Yai, Thailand

  • Investigative Site

    Khlong Luang, Thailand

  • Investigative Site

    Khon Kaen, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.